Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Well Before Symptoms Appear A Fatal Brain Disease Is At Work
University of Florida scientists have discovered why a paralyzing brain disorder speeds along more rapidly in some patients than others - a finding that may finally give researchers an entry point toward an effective treatment for amyotrophic lateral sclerosis, often referred to as ALS or Lou Gehrig"s disease.
generic viagra online
Obama Issues Directive To Enact New Embryonic Stem Cell Research Rules
President Obama on Thursday issued a directive to federal agencies to begin following new NIH guidelines on federally funded embryonic stem cell research, Reuters/New York Times reports (Reuters/New York Times, 7/30). NIH announced the final guidelines earlier this month. The guidelines assess whether newly created embryonic stem cell lines can be used for federally funded research, as well as clarify how old lines will be evaluated (Daily Women"s Health Policy Report, 7/7).In March, Obama overturned President George W. Bush"s policy limiting federal funding of embryonic stem cell research. In a statement Thursday, Obama said, "I hereby direct the heads of executive departments and agencies that support and conduct stem cell research to adopt these guidelines, to the fullest extent practicable in light of legal authorities and obligations" (Reuters/New York Times, 7/30).
News of the day
New Powder Speeds Healing Of Difficult Foot Wounds
Foot complications, such as open wounds and ulcers, can be one of the most difficult ailments for a podiatrist to treat. However, a new wound dressing powder, which acts very much like a layer of skin, is proving to speed the healing time and reduce the amount of pain that a patient suffering from a serious foot ulcer would normally experience. This includes open sores on the feet as a result of inflammatory bowel disease, diabetes or skin cancer. The study results will be released at the American Podiatric Medical Association"s (APMA) 97th Annual Scientific Meeting in Toronto, July 30 - August 2, 2009, and will highlight the powder"s unique ability to rapidly heal foot wounds and advance the treatment patients currently receive.
Mental Health

Inoperable Colon Cancer Responds To New Treatment

With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation"s new protocol. The Tennessee patient"s early results mirror their successes in battling colon cancer and other very aggressive malignancies. The most recent colon cancer patient is a man in his late fifties who had an extensive cancer of the lower colon diagnosed in early 2008. Initially his doctors recommended surgical resection in an operation that would have removed all the organs of his lower abdomen and pelvis; however, it was determined that he would be unlikely to survive the procedure. Chemotherapy was tried, but was ineffective. He visited NeoPlas Innovation"s Nashville clinic in the spring of 2009 and began the new outpatient treatment. Two months later, CT scans have shown that the cancer has regressed dramatically. The patient"s symptoms are resolving in step with the response, with improvements in appetite and digestion and the regaining of lost weight. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are results from one patient, so no conclusions can be drawn. But this is consistent with the favorable responses we"re seeing in the great majority of our patients, including those with colon cancer." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma, mesothelioma and certain sarcomas. It can be considered for other patients on a case-by-case basis. The new treatment is an off-label combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers" growth and spread in as few as eight weeks of treatment. In many cases, such as this one, patients have experienced active regression of tumors. The medicines used have the advantage of being safe and well tolerated. Fatigue is the most notable side effect of NeoPlas Innovation"s cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment. NeoPlas Innovation"s web site, http://www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100. NeoPlas Innovation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009